Donna Hodges
Family · Jackson, MSNPI 1932272200
Payments from drug & device makers
Across 208 payments — averaging $37.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$4K
- Lilly USA, LLC$1K
- Amgen$509
- AstraZeneca$416
- Novo Nordisk$335
- Bayer$274
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$3,87549%
- Travel & lodging$881%
- Food & beverage$3,92850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 16 | $3,860 |
| Lilly USA, LLC | 51 | $1,089 |
| Amgen | 31 | $509 |
| AstraZeneca(2 entities) | 11 | $416 |
| Novo Nordisk | 21 | $335 |
| Bayer | 10 | $274 |
| Radius Health, Inc. | 10 | $240 |
| Insulet Corporation | 7 | $190 |
| Abbott | 6 | $120 |
| AbbVie | 7 | $117 |
| Sanofi-aventis U.S. LLC | 6 | $114 |
| Novartis | 5 | $107 |
| Tandem Diabetes Care, Inc. | 5 | $97 |
| Corcept Therapeutics | 4 | $76 |
| Medtronic | 3 | $56 |
| Sequel Med Tech, LLC | 3 | $56 |
| Xeris Pharmaceuticals, Inc. | 3 | $54 |
| Dexcom, Inc. | 2 | $36 |
| RGH Enterprises LLC | 1 | $27 |
| Astellas Pharma US Inc | 1 | $26 |
| Johnson & Johnson | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,891 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 292 | $368,994 |
| MounjaroTirzepatide | 275 | $334,398 |
| Tresiba Flextouch U-200Insulin Degludec | 183 | $162,674 |
| JardianceEmpagliflozin | 140 | $146,299 |
| TrulicityDulaglutide | 96 | $124,367 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $88,403 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $62,385 |
| Tresiba Flextouch U-100Insulin Degludec | 96 | $55,444 |
| FarxigaDapagliflozin Propanediol | 70 | $49,514 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 32 | $42,990 |
| Novolog FlexpenInsulin Aspart | 188 | $40,674 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 20 | $35,118 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 22 | $31,781 |
| TymlosAbaloparatide | 11 | $29,337 |
| RybelsusSemaglutide | 24 | $26,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,089 | $462,838386 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog, Novolog Mix 70-30 | $335 | $440,368391 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $3,860 | $178,080162 claims |
| AstraZenecaFarxiga | $416 | $49,51470 claims |
| Radius Health, Inc.Tymlos | $240 | $29,33711 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $114 | $11,49914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Jackson
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Leondrea CollinsJackson$28K
- Elizabeth WilliamsJackson$18K
- Anna WalleyJackson$17K
- Teresa SpencerJackson$16K
- Catherine PageJackson$14K
- Mollie DotyJackson$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.